Kabra Drugs Q2 FY27 Results Due After ₹46.22 Crore June Revenue

Kabra Drugs Ltd is scheduled to announce its Q2 FY27 financial results on November 6, 2026, following standalone revenue of ₹46.22 crore in the June 2026 quarter, up 546.4% year-on-year. The upcoming disclosure will show whether the company sustained the revenue growth and profitability reported in recent quarters.

When will Kabra Drugs announce Q2 FY27 results?

Kabra Drugs has scheduled a board meeting on November 6, 2026, to consider and approve unaudited financial results for the September quarter of FY27. The company issued the board-meeting intimation on October 30, placing it among listed companies due to report September-quarter numbers that day.

The company also closed its trading window from October 1, 2026, until 48 hours after the Q2 FY27 results are declared. Such closures are part of listed-company compliance processes intended to restrict trading by designated persons while unpublished price-sensitive information is being prepared and considered.

The September-quarter figures were not included in the available information. Investors therefore have a confirmed reporting date, but not a reported revenue, profit, margin or earnings-per-share figure for Q2 FY27 at this stage.

What did Kabra Drugs report in the June 2026 quarter?

Kabra Drugs reported standalone sales of ₹46.22 crore for the June 2026 quarter, compared with ₹7.15 crore in the June 2025 quarter. This represented year-on-year revenue growth of 546.4%, based on the quarterly data provided.

Expenses rose to ₹43.43 crore in June 2026 from ₹7.67 crore a year earlier. Operating profit was ₹2.79 crore, compared with an operating loss of ₹0.52 crore in June 2025. The resulting operating profit margin was 6.04% for the June 2026 quarter.

Net profit for the June 2026 quarter stood at ₹2.12 crore, reversing a net loss of ₹0.50 crore in the corresponding quarter of the previous year. The quarterly net profit margin was 4.6%, according to the results data.

How has Kabra Drugs' profitability changed recently?

Kabra Drugs' quarterly data shows a move from losses to profits during FY26 and into the June 2026 quarter. Sales were reported at nil through the March 2025 quarter in the data set, before reaching ₹7.15 crore in June 2025, ₹19.76 crore in September 2025, ₹30.42 crore in December 2025 and ₹35.41 crore in March 2026.

Profitability has varied while revenue expanded. The company reported operating profit of ₹2.04 crore in September 2025, ₹2.43 crore in December 2025 and ₹1.34 crore in March 2026, before reporting ₹2.79 crore in June 2026. Operating margins over these four quarters were 10.32%, 7.99%, 3.78% and 6.04%, respectively.

Net profit was ₹1.84 crore in September 2025, ₹2.57 crore in December 2025, ₹1.06 crore in March 2026 and ₹2.12 crore in June 2026. The reported pattern indicates that profits were retained through these four quarters, although margins did not move in a straight line.

What corporate developments are relevant to Kabra Drugs' results?

Kabra Drugs has disclosed board approvals relating to Bhinneka Dwi Persada Indonesia, a proposed artificial intelligence subsidiary, the acquisition of AMR Pharma India Private Limited and the acquisition of Vassmaan Automotive Pvt Ltd. However, the provided information states that these entities do not yet appear as consolidated entities.

This distinction matters when reading the financial statements. The quarterly figures listed for Kabra Drugs are standalone numbers, meaning they reflect the company on that basis rather than financial consolidation of the approved entities. The available information does not provide transaction values, closing dates or financial contributions from these proposed or approved initiatives.

The board has also approved diversification into medical equipment and medical instruments. No revenue contribution from this diversification was disclosed in the information provided. Its relevance to the Q2 FY27 release will depend on what the company reports in its results, notes to accounts or accompanying announcements.

How does the Q2 FY27 announcement matter for investors?

The Q2 FY27 announcement matters because it will provide the next official update after Kabra Drugs' June-quarter revenue of ₹46.22 crore and net profit of ₹2.12 crore. The results can be assessed against the immediately preceding quarter, when revenue was ₹35.41 crore, operating profit was ₹1.34 crore and net profit was ₹1.06 crore.

The data also gives a year-on-year comparison point. In the September 2025 quarter, Kabra Drugs reported sales of ₹19.76 crore, operating profit of ₹2.04 crore and net profit of ₹1.84 crore. The September 2026 results will establish the company’s reported year-on-year trajectory on revenue, operating margin and profit.

No share-price movement, valuation metric, analyst estimate or management earnings guidance was included in the available material. As a result, the immediate market assessment will depend on the figures and disclosures released after the board meeting rather than on a stated consensus expectation.

Conclusion

Kabra Drugs enters its Q2 FY27 results date after reporting a sharp expansion in standalone June-quarter revenue to ₹46.22 crore and a net profit of ₹2.12 crore. Its recent financial record shows a transition from quarterly losses in June 2025 to positive operating and net profit in subsequent reported quarters, with margins remaining variable.

The key event to watch is the November 6, 2026 board meeting and the unaudited September-quarter disclosure that follows. Investors will be able to compare the new figures with June 2026 and September 2025, while looking for any formal update on the approved acquisitions, proposed AI subsidiary and medical-equipment diversification.